Government Affairs
Refine Search
Generics
'Savings of an additional 16 billion euros ($21.9 billion) per annum could be achieved by increasing generic medicines volume in key areas related to the aging population,' Steven Simoens, a professor at the Katholieke Universiteit Leuven said at an event organized by the European Generic medicines Association (EGA) under the patronage of the Belgian Presidency and hosted by Anne Delvaux, Member of the European Parliament. 18 November 2010
Pharmaceutical
'We are breaking the price monopoly of the pharmaceutical industry,' said a government health spokesman, after the German parliament this week passed a drug price reform package to bring down the prices of new branded prescription medicines, which have hitherto been decided mainly by the pharma sector. 12 November 2010
Generics
As negotiations on a European Union-India free trade agreement (FTA) resume in Brussels today, international medical humanitarian organization Medecins Sans Frontieres (MSF) is calling on Europe's highest trade official to halt actions that will dramatically restrict access to affordable generic medicines produced in India. 9 November 2010
Generics
Access to life saving, prescription medicines is under threat, if a controversial Bill is passed by the Australian Parliament, claims the country's Generic Medicines Industry Association (GMiA. The National Health Amendment (Pharmaceutical Benefits Scheme) Bill 2010 gives effect to a new policy that will cut the government's funding of the Pharmaceutical Benefits Scheme (PBS) by A$1.9 billion ($1.86 billion), it says. 8 November 2010
Pharmaceutical
Tuesday's massive victory for US Republicans in securing a majority in the House of Representatives offers some opportunities for the nation's pharmaceutical industry to get certain changes to health care reforms under legislation signed by President Barack Obama's at the start of this year though provisions, but some, including Medicaid rebates and drug discounts for Part D Medicare are here to stay, Eli Lilly chief executive John Lechleiter told the Dow Jones news service. 4 November 2010
Pharmaceutical
Retaking of the House by Republicans in the mid-term elections in the USA brings uncertainty to the health care overhaul in the US, but it's not all bad news, explains Datamonitor's health care analyst Tijana Ignjatovic: 3 November 2010
Pharmaceutical
On the occasion of the Belgian Presidency's ministerial conference on innovation and solidarity in the field of pharmaceuticals, Commissioner for Industry and Entrepreneurship, Antonio Tajani, announced the launch of a process on corporate responsibility in the pharmaceutical industry. 3 November 2010
Pharmaceutical
The UK drug watchdog body, the National Institute for Health and Clinical Excellence (NICE), will no longer be able to deny patients the use of therapies on the National Health Service based on cost effectiveness, as it has done until now, and will only be permitted to adjudicate on efficacy and safety. Instead, groups of general practitioners within the 150 or so Primary Care Trusts will decide which drugs should be funded by the NHS in England and Wales. 2 November 2010
Pharmaceutical
The USA's Government Accountability Office last week publicly released its September 2010 Report to the House Committee on Oversight and Government Reform concerning Drug Safety, titled 'DRUG SAFETY - FDA Has Conducted More Foreign Inspections and Begun to Improve Its Information on Foreign Establishments, but More Progress Is Needed. 2 November 2010
Biotechnology
The USA's Biotechnology Industry Organization (BIO) last week made a call for Congress to repeat a one-time $1 billion program that provides tax credits to small companies that are developing new drugs, saying this will have a positive impact on advancing life-saving therapies and cures for patients, and US biotechnology competitiveness, while helping sustain and create jobs. 1 November 2010
Pharmaceutical
A UK Cancer Drugs Fund of 200 million ($313.4 million) a year to help cancer patients get greater access to cancer drugs that their doctors recommend for them was confirmed yesterday by Health Secretary Andrew Lansley. 28 October 2010
Biotechnology
UK Science Minister David Willetts and Health Minister Lord Howe yesterday jointly launched a world-first initiative to boost partnership between academics, clinicians and the life sciences industry to deliver the medicines of the future faster to UK patients and to secure the UK's position as the global partner of choice for R&D collaboration. 26 October 2010
Pharmaceutical
Latest figures, released by MedTRACK, a biomedical database of Life Science Analytics, show stagnant product development across the Asia Pacific (APAC) region. Only 15% of all drugs development is taking place in APAC, despite this region boasting some of the largest potential growth markets in the world. This compares to 28% in Europe and 55% in the USA. 26 October 2010
Generics
A Filipino pharmaceutical group official has boasted that generic medicines have been saving and improving lives of patients, aiming to debunk misconceptions that generics are ineffective because they are cheap. Eufe Tantia, vice president of the Pharmaceutical and Healthcare Association of the Philippines, claimed that his association's member companies have engaged and invested in R&D to discover innovative medicines and provide better treatment opportunity for patients with lesser costs. 25 October 2010
Pharmaceutical
Despite the UK Coalition government's promises that the health budget will be ring-fenced, the spending review announced on Wednesday by the Chancellor George Osborne (The Pharma Letter October 21), it spells trouble for the health care and pharma sector, according to Tijana Ignjatovic, strategic health care analyst at Datamonitor, commenting on the impact of the Comprehensive Strategic Review (CSR) on the health care and pharmaceutical industry in the UK. 22 October 2010
Biotechnology
In yesterday's announcement by the UK's Coalitions government of massive public spending cuts, the Department for Business, Innovation and Skills (BIS) will reduce its resource budget by 25 per cent. Taking into account anticipated receipts, the cut to capital spending by 2014-15 will be 44 per cent. 21 October 2010
Biotechnology
A new report released by Lateral Economics and launched yesterday at AusBiotech 2010, underscores the social and economic value of medical R&D, said drug industry trade group Medicines Australia's chief executive Brendan Shaw. 21 October 2010
Pharmaceutical
Changes are needed in the remit of the UK drugs watchdog, the National Institute for Health and Clinical Excellence (NICE), to equip it for the future 'value-based' era envisaged by government, according to the trade group the Association of the British Pharmaceutical Industry (ABPI). 20 October 2010
Pharmaceutical
Business Monitor International's projection for Uzbekistan's pharmaceutical market remains largely unchanged this quarter, with its five-year compound annual growth rate (CAGR) forecast at 10.37% in US dollar terms between 2009 and 2014, reaching a total value of 977.51 billion sum ($519 million) by the end of the forecast period. 19 October 2010
Pharmaceutical
Latvia's pharmaceutical market is currently overshadowed by sharp cuts as part of the government's austerity package, which is aimed at securing European Union and International Monetary Fund financing. The country's economy may now be showing signs of a meek recovery but further cuts will help play out Business Monitor International's view that the pharmaceutical market will stagnate at 236 million lats ($377 million) in 2010. 18 October 2010
Pharmaceutical
The nomination of Robert F Kennedy Jr — known as RFK Jr — for the role of US Secretary of the Department of Health and Human Services (HHS) President-elect Donald Trump sent shares in vaccine companies sharply downwards. 22 November 2024
article
The UK government has reappointed BioIndustry Association (BIA) chairman Daniel Mahony as its Life Sciences Investment Envoy. 21 November 2024
Pharmaceutical
The Danish government’s newly-unveiled health reform has been praised for tackling chronic disease care and health inequalities while driving health innovation. 18 November 2024
Pharmaceutical
New research published by the European Federation of Pharmaceutical Industries and Associations (EFPIA) provides in-depth analysis of the economic footprint of the pharmaceutical industry in Europe, across member states and compares Europe to other regions of the world. 18 November 2024
Pharmaceutical
Johnson & Johnson has taken legal action to defend a contentious rebate initiative, filing a lawsuit in the US District Court for the District of Columbia. 15 November 2024
Pharmaceutical
The share prices of Pfizer, GSK, Novavax and other vaccine companies were all markedly lower on Friday. This was not due to the publication of disappointing research results in the sphere, or an ominous stance taken by a major regulator on a key filing, but rather a political development that could spell trouble for the vaccines field as a whole. 15 November 2024
Biotechnology
BeiGene has announced plans to rebrand as BeOne Medicines, a move the cancer specialist says reflects its commitment to fighting cancer through collaboration. 15 November 2024
Pharmaceutical
Danish patients are being offered fewer innovative treatments than Norwegians and Swedes, a new estimate from the Danish Medicines Council shows. 11 November 2024
Pharmaceutical
According to the Swedish pharma trade group Lif, it is positive that, in the updated life science strategy, the government expresses an ambition for Sweden to become more attractive for research investments. 11 November 2024
Pharmaceutical
Li Li, Commissioner of China's National Medical Products Administration (NMPA), and Mette Aaboe Hansen, interim director general of Danish Medicines Agency, have signed a letter of intent to promote bilateral cooperation in regulation of drugs and medical devices. 11 November 2024
Pharmaceutical
Following the news that Donald Trump is the winner of the 2024 US Presidential Election, Morningstar Equity analyst Julie Utterback has published a new note about the impact of this on the managed-care industry. 7 November 2024
Pharmaceutical
UK pharma major AstraZeneca, which has invested heavily in China, hosted a sell-side analyst call on Wednesday (November 6) to discuss the recent media reports about ongoing investigations in China. 7 November 2024
Pharmaceutical
Some of the UK’s leading academics and industry professionals have welcomed Chancellor Rachel Reeves’ £520 million ($669 million) pledge to develop the country’s medicine manufacturing capabilities. 6 November 2024
Pharmaceutical
European regulators will decide by December 6 whether Novo Holdings, the controlling shareholder of Danish pharma giant Novo Nordisk, can finalize its $16.5 billion acquisition of contract drug manufacturer Catalent. 5 November 2024
Pharmaceutical
The Danish government is rolling out the red carpet and welcomes several pharmaceutical companies. 4 November 2024
Generics
Medicines for Europe has launched a study of market barriers faced by European generics and biosimilar pharmaceutical companies operating in 11 key third-country markets. 31 October 2024
Pharmaceutical
Following the first Labour budget for 14 years, the Association of the British Pharmaceutical Industry (ABPI) welcomes Chancellor Rachel Reeves’ measures to improve UK life sciences competitiveness. 30 October 2024
Pharmaceutical
HOPO Therapeutics has been awarded a contract valued at up to $226 million from the Biomedical Advanced Research and Development Authority (BARDA). 29 October 2024
Pharmaceutical
The Danish government has presented part of the plan for a future life science strategy, which has been welcomed by the industry. 28 October 2024
Biotechnology
Legend Biotech has removed Genscript Biotech as its majority shareholder, in a move coinciding with rising US concerns over Chinese ties within the biotech sector. 24 October 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze